These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate. Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197 [TBL] [Abstract][Full Text] [Related]
5. Particle contamination of parenteralia and in-line filtration of proteinaceous drugs. Werner BP; Winter G Int J Pharm; 2015 Dec; 496(2):250-67. PubMed ID: 26556624 [TBL] [Abstract][Full Text] [Related]
6. Overview of the International Conference on Particle Detection, Metrology, and Control. Knapp JZ; Barber TA J Parenter Sci Technol; 1990; 44(5):257-63. PubMed ID: 1979082 [TBL] [Abstract][Full Text] [Related]
7. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Particulate Matter in Liquid-Finished Dosage Forms. Duchek J; Havasi B PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612 [TBL] [Abstract][Full Text] [Related]
9. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product. Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460 [TBL] [Abstract][Full Text] [Related]
10. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885 [TBL] [Abstract][Full Text] [Related]
11. Recommended guidelines for quality assurance in hospital centralized intravenous admixture services. National Coordinating Committee on Large Volume Parenterals. Am J Hosp Pharm; 1980 May; 37(5):645-55. PubMed ID: 7386471 [TBL] [Abstract][Full Text] [Related]
12. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products. Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961 [TBL] [Abstract][Full Text] [Related]
13. Cumulative sum control charts for admixture quality control. Sanford RL Am J Hosp Pharm; 1980 May; 37(5):655-9. PubMed ID: 7386472 [TBL] [Abstract][Full Text] [Related]
14. Particulate matter determination in LVPs produced in Dutch hospital pharmacies, Part 1: Particle-counting accuracy. Van der Veen J; Verbrugge P; Van de Vaart FJ; Boom FA PDA J Pharm Sci Technol; 1997; 51(2):81-8. PubMed ID: 9146039 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of two sterility testing methods for intravenous admixtures. Condella F; Eichelberger K; Foote LC; Griffin RE Hosp Pharm; 1980 Jun; 15(6):305-10. PubMed ID: 10247270 [TBL] [Abstract][Full Text] [Related]
16. Qaulity-control plan for intravenous admixture programs. II: Validation of operator technique. Morris BG; Avis KE; Bowles GC Am J Hosp Pharm; 1980 May; 37(5):668-72. PubMed ID: 7386475 [TBL] [Abstract][Full Text] [Related]
17. In-use physicochemical and microbiological stability of biological parenteral products. Ricci MS; Frazier M; Moore J; Cromwell M; Galush WJ; Patel AR; Adler M; Altenburger U; Grauschopf U; Goldbach P; Fast JL; Krämer I; Mahler HC Am J Health Syst Pharm; 2015 Mar; 72(5):396-407. PubMed ID: 25694415 [No Abstract] [Full Text] [Related]
18. Particulate matter in parenteral products: a review. Borchert SJ; Abe A; Aldrich DS; Fox LE; Freeman JE; White RD J Parenter Sci Technol; 1986; 40(5):212-41. PubMed ID: 3540253 [No Abstract] [Full Text] [Related]
19. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress. Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805 [TBL] [Abstract][Full Text] [Related]